{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115934","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.382283+00:00","generated_at":"2026-06-22T03:42:13.920818+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Natera Q3 revenue $210.6M (+33% YoY), raises FY22 guidance to $810M-$830M","bullets":["Total revenues $210.6M, up 33% YoY; test volumes 517,500 (+27% YoY).","Net loss $121.5M ($1.25/share) vs $151.3M ($1.63) in Q3 2021.","Gross margin 44.7% vs 48.5% YoY due to labor/overhead costs; 2022 guidance raised by $40M.","Oncology tests 53,000 (+153% YoY); Signatera pan-cancer contract with VA and Medicare IO monitoring set at $7,489.","Board completes investigation, finds short seller allegations of wrongdoing unfounded."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115934","json":"https://secwatch.observer/filing/0001104659-22-115934.json","markdown":"https://secwatch.observer/filing/0001104659-22-115934.md","text":"https://secwatch.observer/filing/0001104659-22-115934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465922115934/0001104659-22-115934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465922115934/tm2229989d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:42:13.920818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87f6def0d945ff50efa146ff9ae4e9898ae2590c","claim":"Natera, Inc. reported third quarter ended September 30, 2022 results: revenue $210.6 million, net income net loss of $121.5 million, EPS ($1.25) per diluted share. Guidance raised.","evidence_excerpt":"Third Quarter Ended September 30, 2022 Financial Results Total revenues were $210.6 million in the third quarter of 2022 compared to $158.1 million for the third quarter of 2021, an increase of 33.2%. Product revenues were $199.8 million in the third quarter of 2022 compared to $153.9 million in the third quarter of 2021, an increase of 29.8%. The growth in product revenues was driven by an increase in test volumes compared to the third quarter of 2021. Natera processed approximately 517,500 tests in the third quarter of 2022, including approximately 502,900 tests accessioned in its laboratory. This compares to approximately 407,300 tests processed in the third quarter of 2021, including approximately 394,200 tests accessioned in its laboratory, an increase of 27.1% for the quarter. In the three months ended September 30, 2022, Natera recognized revenue on approximately 483,000 tests for which results were reported to customers in the period (tests reported), including approximately 46","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604821/000110465922115934/0001104659-22-115934-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$210.6 million"},{"label":"Net income","value":"net loss of $121.5 million"},{"label":"EPS","value":"($1.25) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}